85 related articles for article (PubMed ID: 15645425)
1. Novel murine B-cell lymphoma/leukemia model to study BCL2-driven oncogenesis.
Meijerink JP; Van Lieshout EM; Beverloo HB; Van Drunen E; Mensink EJ; Macville M; Pieters R
Int J Cancer; 2005 May; 114(6):917-25. PubMed ID: 15645425
[TBL] [Abstract][Full Text] [Related]
2. Bcl-x(L) and Akt cooperate to promote leukemogenesis in vivo.
Karnauskas R; Niu Q; Talapatra S; Plas DR; Greene ME; Crispino JD; Rudin CM
Oncogene; 2003 Feb; 22(5):688-98. PubMed ID: 12569361
[TBL] [Abstract][Full Text] [Related]
3. Rearrangement of the 5' cluster region of the BCL2 gene in lymphoid neoplasm: a summary of nine cases.
Yabumoto K; Akasaka T; Muramatsu M; Kadowaki N; Hayashi T; Ohno H; Fukuhara S; Okuma M
Leukemia; 1996 Jun; 10(6):970-7. PubMed ID: 8667654
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic targeting of Bcl-2 family for treatment of B-cell malignancies.
Huang J; Fairbrother W; Reed JC
Expert Rev Hematol; 2015 Jun; 8(3):283-97. PubMed ID: 25912824
[TBL] [Abstract][Full Text] [Related]
5. Transgenic N-myc mouse model for indolent B cell lymphoma: tumor characterization and analysis of genetic alterations in spontaneous and retrovirally accelerated tumors.
Sheppard RD; Samant SA; Rosenberg M; Silver LM; Cole MD
Oncogene; 1998 Oct; 17(16):2073-85. PubMed ID: 9798678
[TBL] [Abstract][Full Text] [Related]
6. Dysregulated TRAF3 and BCL2 Expression Promotes Multiple Classes of Mature Non-hodgkin B Cell Lymphoma in Mice.
Perez-Chacon G; Adrados M; Vallejo-Cremades MT; Lefebvre S; Reed JC; Zapata JM
Front Immunol; 2018; 9():3114. PubMed ID: 30687320
[TBL] [Abstract][Full Text] [Related]
7. Bcl-2, Bax and p53 expression in B-CLL in relation to in vitro survival and clinical progression.
Aguilar-Santelises M; Rottenberg ME; Lewin N; Mellstedt H; Jondal M
Int J Cancer; 1996 Apr; 69(2):114-9. PubMed ID: 8608978
[TBL] [Abstract][Full Text] [Related]
8. A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis.
Yu D; Thomas-Tikhonenko A
Oncogene; 2002 Mar; 21(12):1922-7. PubMed ID: 11896625
[TBL] [Abstract][Full Text] [Related]
9. Stepwise progression of B cell malignancy occurred in a bone marrow stromal cell-dependent pre-B cell clone.
Ogawa M; Ikuta K; Katsura Y; Nishikawa S
Leukemia; 1989 Apr; 3(4):282-8. PubMed ID: 2784522
[TBL] [Abstract][Full Text] [Related]
10. Synergistic effect of Bcl2, Myc and Ccnd1 transforms mouse primary B cells into malignant cells.
Nakagawa M; Tsuzuki S; Honma K; Taguchi O; Seto M
Haematologica; 2011 Sep; 96(9):1318-26. PubMed ID: 21606168
[TBL] [Abstract][Full Text] [Related]
11. p53 apoptotic response to DNA damage dependent on bcl2 but not bax in head and neck squamous cell carcinoma lines.
Crowe DL; Sinha UK
Head Neck; 2006 Jan; 28(1):15-23. PubMed ID: 16302195
[TBL] [Abstract][Full Text] [Related]
12. U-2973, a novel B-cell line established from a patient with a mature B-cell leukemia displaying concurrent t(14;18) and MYC translocation to a non-IG gene partner.
Boström H; Leuchowius KJ; Hallböök H; Nordgren A; Thörn I; Thorselius M; Rosenquist R; Söderberg O; Sundström C
Eur J Haematol; 2008 Sep; 81(3):218-25. PubMed ID: 18510704
[TBL] [Abstract][Full Text] [Related]
13. Wild-type p53-triggered apoptosis is inhibited by bcl-2 in a v-myc-induced T-cell lymphoma line.
Wang Y; Szekely L; Okan I; Klein G; Wiman KG
Oncogene; 1993 Dec; 8(12):3427-31. PubMed ID: 8247547
[TBL] [Abstract][Full Text] [Related]
14. Quantitation of bcl-2 oncogene in cultured lymphoma/leukemia cell lines and in primary leukemia B-cells by a highly sensitive RT-PCR method.
Quattrone A; Papucci L; Santini V; Schiavone N; Noferini D; Calastretti A; Copreni E; Morelli S; Rossi Ferrini PL; Nicolin A
Haematologica; 1995; 80(6):495-504. PubMed ID: 8647513
[TBL] [Abstract][Full Text] [Related]
15. Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model.
Cotter FE; Johnson P; Hall P; Pocock C; al Mahdi N; Cowell JK; Morgan G
Oncogene; 1994 Oct; 9(10):3049-55. PubMed ID: 8084613
[TBL] [Abstract][Full Text] [Related]
16. Frequent p53 gene involvement in splenic B-cell leukemia/lymphomas of possible marginal zone origin.
Baldini L; Fracchiolla NS; Cro LM; Trecca D; Romitti L; Polli E; Maiolo AT; Neri A
Blood; 1994 Jul; 84(1):270-8. PubMed ID: 8018922
[TBL] [Abstract][Full Text] [Related]
17. Constitutive versus cell cycle regulation of c-myb mRNA expression correlates with developmental stages in murine B lymphoid tumors.
Catron KM; Purkerson JM; Isakson PC; Bender TP
J Immunol; 1992 Feb; 148(3):934-42. PubMed ID: 1730880
[TBL] [Abstract][Full Text] [Related]
18. Bcl-2 is an apoptotic target suppressed by both c-Myc and E2F-1.
Eischen CM; Packham G; Nip J; Fee BE; Hiebert SW; Zambetti GP; Cleveland JL
Oncogene; 2001 Oct; 20(48):6983-93. PubMed ID: 11704823
[TBL] [Abstract][Full Text] [Related]
19. Germinal center-derived signals act with Bcl-2 to decrease apoptosis and increase clonogenicity of drug-treated human B lymphoma cells.
Walker A; Taylor ST; Hickman JA; Dive C
Cancer Res; 1997 May; 57(10):1939-45. PubMed ID: 9157989
[TBL] [Abstract][Full Text] [Related]
20. Expression of the NF-kappaB targets BCL2 and BIRC5/Survivin characterizes small B-cell and aggressive B-cell lymphomas, respectively.
Tracey L; Pérez-Rosado A; Artiga MJ; Camacho FI; Rodríguez A; Martínez N; Ruiz-Ballesteros E; Mollejo M; Martinez B; Cuadros M; Garcia JF; Lawler M; Piris MA
J Pathol; 2005 Jun; 206(2):123-34. PubMed ID: 15880597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
